Alyssa Levin
Director of Finance/CFO at NKARTA, INC.
Net worth: 605 360 $ as of 2024-03-30
Profile
Alyssa Levin is currently the Chief Financial & Business Officer at Nkarta, Inc. She previously worked as the Chief Financial Officer at ViaCyte, Inc. She received an undergraduate degree from the University of British Columbia and a graduate degree from Edwards School of Business.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
NKARTA, INC.
0.11% | 2024-01-03 | 56,000 ( 0.11% ) | 605 360 $ | 2024-03-30 |
Alyssa Levin active positions
| Companies | Position | Start |
|---|---|---|
| NKARTA, INC. | Director of Finance/CFO | 2023-07-04 |
Former positions of Alyssa Levin
| Companies | Position | End |
|---|---|---|
ViaCyte, Inc.
 ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Director of Finance/CFO | 2023-07-04 |
Training of Alyssa Levin
| University of British Columbia | Undergraduate Degree |
| Edwards School of Business | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| NKARTA, INC. | Health Technology |
| Private companies | 1 |
|---|---|
ViaCyte, Inc.
ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Alyssa Levin
